Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
68°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Zynerba Pharmaceuticals, Inc.
Important Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and Instructions
October 04, 2023
From
Zynerba Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ZYNE
Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023
September 29, 2023
From
Zynerba Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ZYNE
Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research Symposium
September 14, 2023
From
Zynerba Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ZYNE
Zynerba Pharmaceuticals Announces New Date for Reconvened Annual Meeting
August 08, 2023
From
Zynerba Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ZYNE
Zynerba Pharmaceuticals Announces New Date for Reconvened Annual Meeting
July 25, 2023
From
Zynerba Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ZYNE
Zynerba Pharmaceuticals Announces Further Adjournment of Annual Meeting
June 28, 2023
From
Zynerba Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ZYNE
Zynerba Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
June 20, 2023
From
Zynerba Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ZYNE
Zynerba Pharmaceuticals Announces Partial Adjournment of Annual Meeting
June 13, 2023
From
Zynerba Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ZYNE
Zynerba Pharmaceuticals Announces Podium and Poster Presentations at the American Society of Clinical Psychopharmacology Annual Meeting
May 23, 2023
From
Zynerba Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ZYNE
Zynerba Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Highlights
May 15, 2023
From
Zynerba Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ZYNE
Zynerba Pharmaceuticals Presents Data on Zygel™ at the 55th Gatlinburg Conference
April 12, 2023
From
Zynerba Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ZYNE
Zynerba Pharmaceuticals Announces Poster Presentations at the 55th Gatlinburg Conference
April 05, 2023
From
Zynerba Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ZYNE
Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
March 28, 2023
From
Zynerba Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ZYNE
Zynerba Pharmaceuticals Confirms Not Holding Cash Deposits or Securities at Silicon Valley Bank
March 13, 2023
From
Zynerba Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ZYNE
Zynerba Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
March 07, 2023
From
Zynerba Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ZYNE
Zynerba Pharmaceuticals to Present at the Cowen 43rd Annual Health Care Conference
March 01, 2023
From
Zynerba Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ZYNE
Zynerba Pharmaceuticals Announces Publication in the Journal of Neurodevelopmental Disorders Describing the Role of the Endocannabinoid System and Cannabidiol Therapy in Fragile X Syndrome
January 11, 2023
From
Zynerba Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ZYNE
Zynerba Pharmaceuticals Announces Update on RECONNECT, the Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome
December 21, 2022
From
Zynerba Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ZYNE
Zynerba Pharmaceuticals Announces Positive Long-Term Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at the Annual Meeting of the American College of Neuropsychopharmacology
December 05, 2022
From
Zynerba Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ZYNE
Zynerba Pharmaceuticals Announces Poster Presentation at the Annual Meeting of the American College of Neuropsychopharmacology
November 29, 2022
From
Zynerba Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ZYNE
Zynerba Pharmaceuticals Announces Publication of Data from Phase 3 CONNECT-FX Study of Zygel™ in the Journal of Neurodevelopmental Disorders
November 28, 2022
From
Zynerba Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ZYNE
Zynerba Pharmaceuticals Announces European Commission Has Granted Orphan Drug Designation for Zygel™ in 22q11.2 Deletion Syndrome
November 15, 2022
From
Zynerba Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ZYNE
Zynerba Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Highlights
November 14, 2022
From
Zynerba Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ZYNE
Zynerba Pharmaceuticals Announces Issuance of New U.S. Patent for Zygel™ for the Treatment of 22q11.2 Deletion Syndrome
November 02, 2022
From
Zynerba Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ZYNE
Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit
October 17, 2022
From
Zynerba Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ZYNE
Zynerba Pharmaceuticals Announces Poster Presentation at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit
October 10, 2022
From
Zynerba Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ZYNE
Zynerba Pharmaceuticals Announces Issuance of New U.S. Patent for Zygel™
October 06, 2022
From
Zynerba Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ZYNE
Zynerba Pharmaceuticals to Participate in the Cantor Neurology & Psychiatry Conference
September 29, 2022
From
Zynerba Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ZYNE
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.